StockNews.com Initiates Coverage on ObsEva (NASDAQ:OBSV)

Equities researchers at StockNews.com initiated coverage on shares of ObsEva (NASDAQ:OBSV) in a report released on Saturday. The firm set a “hold” rating on the stock.

ObsEva Stock Performance

Shares of ObsEva stock opened at $0.00 on Friday. ObsEva has a 52-week low of $0.08 and a 52-week high of $2.14. The stock has a market capitalization of $155,942.00, a price-to-earnings ratio of 0.00 and a beta of 0.68. The company has a fifty day moving average of $0.02 and a 200-day moving average of $0.04.

Institutional Investors Weigh In On ObsEva

A number of institutional investors have recently made changes to their positions in OBSV. Two Sigma Investments LP purchased a new stake in ObsEva during the 3rd quarter valued at $25,000. Virtu Financial LLC purchased a new stake in ObsEva during the 1st quarter valued at $30,000. XTX Topco Ltd boosted its position in ObsEva by 33.9% during the 1st quarter. XTX Topco Ltd now owns 79,757 shares of the company’s stock valued at $120,000 after buying an additional 20,196 shares during the period. Millennium Management LLC purchased a new stake in ObsEva during the 2nd quarter valued at $192,000. Finally, Credit Suisse AG boosted its position in ObsEva by 8.7% during the 3rd quarter. Credit Suisse AG now owns 1,577,118 shares of the company’s stock valued at $224,000 after buying an additional 126,812 shares during the period. Hedge funds and other institutional investors own 17.52% of the company’s stock.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.